Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Lexaria Bioscience's Enterprise Value is $13.49 Mil.
Lexaria Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 was $-7.43 Mil. Therefore, Lexaria Bioscience's EV-to-OCF for today is -1.82.
The historical rank and industry rank for Lexaria Bioscience's EV-to-OCF or its related term are showing as below:
LEXX'
s EV-to-OCF Range Over the Past 10 Years
Min: -73.78 Med: -6.33 Max: -0.13
Current: -1.82
During the past 13 years, the highest EV-to-OCF of Lexaria Bioscience was -0.13. The lowest was -73.78. And the median was -6.33.
LEXX's EV-to-OCF is ranked worse than 59.4% of 1409
companies
in the Biotechnology industry
Industry Median: -3.68
vs LEXX: -1.82
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lexaria Bioscience's PE Ratio (TTM) for today is calculated as:
Lexaria Bioscience's share price for today is $10.60.
Lexaria Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lexaria Bioscience EV-to-OCF Related Terms
Lexaria Bioscience EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's EV-to-OCF falls into.
Lexaria Bioscience's current Enterprise Value is $13.49 Mil.
Lexaria Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a EV-to-OCF of -1.82 as of Aug. 24, 2026. According to the industry distribution chart, Lexaria Bioscience ranks #837 out of 1409 companies in the Biotechnology industry, placing it in the top 59.4%.
Is Lexaria Bioscience's EV-to-OCF too high?
Lexaria Bioscience's current EV-to-OCF is -1.82. Based on the distribution chart, Lexaria Bioscience ranks #837 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lexaria Bioscience has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's EV-to-OCF compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #837 out of 1409 companies for EV-to-OCF. This places Lexaria Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Lexaria Bioscience's current EV-to-OCF is -1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $10.60 — trading 97% above its estimated fair value. The current EV-to-OCF is -1.82. Lexaria Bioscience's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current EV-to-OCF is -1.82 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $10.60 is trading 97% above its estimated GF Value™ of $5.38.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
EV-to-OCF: -1.82
GF Value™: $5.38 vs. price of $10.60 (97% above fair value)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
36GF Score
Get the complete analysis for LEXX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
